Capula Management Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX

Capula Management Ltd bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 145,300 shares of the company’s stock, valued at approximately $1,454,000.

Several other large investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after buying an additional 4,178 shares during the period. Millennium Management LLC increased its stake in shares of Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after buying an additional 512,842 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Amneal Pharmaceuticals in the first quarter valued at approximately $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Amneal Pharmaceuticals by 5.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after acquiring an additional 16,536 shares in the last quarter. Finally, Savant Capital LLC acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $150,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 2.3%

Shares of AMRX opened at $11.83 on Friday. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of 51.44 and a beta of 1.35. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $15.42. The stock has a 50 day moving average price of $13.78 and a 200 day moving average price of $12.00.

Analyst Ratings Changes

AMRX has been the subject of several analyst reports. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, March 6th. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Barclays began coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.